Our introduction to Maja Thiele includes not only her academic background and interests, but also a first-time “One Thing…” answer and her role in LiverAIM, the largest randomized control trial ever envisioned in SLD.
SLD Think Tank 2023 co-chairs Jörn Schattenberg and Jeff Lazarus and participants Maja Thiele and Mike Betel join Louise Campbell and Roger Green to discuss high points of the recent Barcelona meting.
Louise Campbell and Roger Green interview Stephen Harrison as part of our year-end series for 2022, our last individual interview with Stephen.
Panelists reflecting on Stephen Harrison share what they consider his most important and lasting professional accomplishments.
Panelists reflect on their personal memories of Stephen Harrison
Panelists share some of their favorite “Harrisonisms” – unique phrases and verbal memes from Stephen Harrison.
Colleagues and friends Manal Abdelmalek and Naim Alkhouri join the Surfers in the first of what will be several conversations remembering our co-founder, the SLD master Stephen Harrison.
This conversation looks back to highlights of SurfingMASH’s coverage of GLI’s 2023 event, International NASHDAY.
This closing conversation centers first around Roger’s use of the “blind people touching an elephant” metaphor to describe the complexity of MASH, and then creates a second goal, this time for providers to “rule out the liver.”
The group, including co-hosts Louise Campbell and Roger Green along with guests Jeff McIntyre and Mike Betel, dives deeper into the care challenges and barriers confronting MASH patient care today.
The conversation shifts to look first at challenges caused by explosion in the use of incretin agonists like GLP-1s to treat obesity and diabetes and second by the opportunities creating by on-site scanning.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre describes the rational behind GLI’s 2024 theme, after which Mike Betel and Roger Green share reactions.
On April 23, SurfingMASH Co-founder Stephen Harrison passed away unexpectedly. This episode starts with panelists each sharing a memory of Stephen.
Patient advocates Jeff McIntyre (Global Liver Institute) and Mike Betel (Fatty Liver Alliance, Liver Action Network) join Louise Campbell and Roger Green to discuss GLI’s premier MASH patient event, now known as Global Fatty Livery Day.
This week’s vault episode looks back to last September, when Laurent Castera joined the Surfers to discuss different roles that NITs can play in MASH drug development and patient assessment.
This final conversation about MASH drug development includes continued discussion of combination therapies and a discussion on NITs’ vital role in speeding the process and making it more efficient.
Sven Francque and William Alazawi join the Surfers discuss the impact of concomitant metabolic therapies like incretin agonists on MASH Drug Development.
Sven Francque and William Alazawi join the Surfers to discuss challenges in creating efficacy endpoints, and also areas where development has improved since 2020during MASH Drug Development.
Sven Francque and William Alazawi join the Surfers to discuss challenges in proper scoring and categorization of efficacy endpoints during MASH Drug Development.
Sven Francque joins guest William Alazawi and the Surfers to discuss high points from his 2023 article on the MASH drug development graveyard in 2023
Sven Francque and William Alazawi join the Surfers to to consider how we have translated the lessons of previous failed trials into better designs that produce successful trials.
This 2023 conversation raises the question of prescribing MASH drugs adjunctive to other therapies, most notably HCC.
This final conversation touches on prescribing models and the increasing challenge keeping patients in long-term clinical trials, after which Roger Green asks a final question.
This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.
Michael Charlton, Jörn Schattenberg and Louise Campbell each identify a specific paper or event they consider exciting and important.
Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine
Michael Charlton describes the impact of Rezdiffra on practices and procedures in his clinic
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
Hepatologist Tim Jobson, co-founder of Predictive Health Intelligence, joins Louise Campbell and Roger Green to provide an update on PHI’s work and discuss implications for databases, patient recruitment and special population issues.
This week’s vault exercise looks back to our coverage of The EASL Congress 2023, when the panel discusses the role of FIB-4 and other elements in the clinical care pathway.
Hannes Hagstrom and the Surfers consider how the need for predictive biomarkers will co-evolve with in-office screening as multiple drugs come to market.
Hannes Hagstrom and the Surfers consider the ways that increased access to in-office screening will affect clinical care pathways, with special focus on the role of primary care practices.
Hannes Hagstrom joins the Surfers to explore the ways that increased access to and awareness of VCTE or other in-office scanning will improve MASLD therapy.
Hannes Hagstrom join the Surfers in discussing studies that demonstrate the value of different nutritional approaches in driving improved liver health.
Hannes Hagstrom joins the Surfers to discuss recent studies focused on VCTE. , both in its prognostic capability for MASLD patients when compared to biopsy and separately as a therapeutic agent.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
Fatty Liver Alliance Founder Mike Betel joins Roger Green to consider how patient incentives to participate in MASH clinical trials might need to change now that prescribers have an approved drug for treating MASH patients.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
MASLD patient advocates consider the impact Rezdiffra approval and accompanying promotion and education might have on the U.S. healthcare system.
This conversation focuses on how the role of MASLD patient advocates might change and expand in the aftermath of Rezdiffra being approved. MAFLD patient advocates consider how their roles might change and expand now that Rezdiffra has been approved.
Patient advocates, led by GLI’s Jeff McIntyre, discuss advocates’ goals for a MASH drug label and the steps they took to communicate this information to FDA.
Five leading MASLD patient advocates discuss their initial reactions when Rezdiffra became the first MASH drug approved in the US on March 14.
Leading patient advocates help the Surfers identify the target MASH patients for Rezdiffra and discuss Madrigal’s extensive patient support program.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
The conversation on Rezdiffra, the first MASH drug, wraps up with the panelists answering a inviation to discuss any other issues of interest that had not arisen in the conversation.
This conversation focuses on what panelists believe to be the major lessons the BioPharma industry should take from Madrigal’s success in bring Rezdiffra to launch.
The launch of Rezdiffra raises this pivotal question: which MASH patients are the correct initial targets for the first MASH drug?
As panelists ponder practical issues about when and to whom to prescribe Rezdiffra, they consider the benefits and shortcomings of existing NITs.
SurfingMASH’s coverage of the Rezdiffra approval shifts to a seemingly tangential topic: impact of drug approval on patient adherence with lifestyle recommendations.
Key Opinion Leaders for Europe and the US join the Surfers the day after the first MASH drug, Rezdiffra, was approved, to discuss how they heard the news and what kinds of patients they envision as initial targets.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
The conversation comes from the first time we discussed MASEF on the podcast. Lead author Mazen Noureddin joined the Surfers to discuss his paper and the potential for this test.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
This conversation includes two separate themes: the rationale and impact around the price of resmetirom, and the impact of GLP-1s on resmetirom use in patients with MASH.
This conversation looks at different strategies to improve NITs in the diagnosis and staging of patients with advanced MASH Fibrosis.
This conversation focuses on why it will be challenging to use currently-available NITs to stage patients with advanced MASH fibrosis (F2/F3) accurately with current test options.
This conversation focuses on why use of NITs is such a pivotal issue for MASH treatment and drug adoption, particularly if, as expected, the first MASH drug is approved this month.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
From 2022: Chris Estes, then from the Center for Disease Analysis Foundation, and Alina Allen from the Mayo Clinic join the Surfers to discuss the creation of a 15-country epidemiology model for MASLD/NAFLD and MASH/NASH and what it tells us about the future path of the disease, and specifically treatment of advanced fibrosis.
As the episode comes to an end, the group winds up focusing on the need for better, more frequent MASH education as a pivotal need if we are to flatten the growth curve of the MASLD pandemic. In the process, the discussion returns to the risk for women and the important role they can play.
Zobair Younossi and the Surfers, including Global NASH Council member Jörn Schattenberg, discuss Zobair’s work through the Global NASH Council and some implications for low SDI vs. high SDI countries.
Zobair Younossi and Louise Campbell lead a discussion that focuses first on slowing the growth of the MASLD pandemic, then on issues specific to menopausal women
Zobair Younossi joins the Surfers to discuss cost and cost effectiveness, including both how it is measured and how stakeholders might think about it, in the context of the MASLD disease burden.
Zobair Younossi discusses the disease burden of MASLD as characterized in his recent publication “Understanding the Burden of Fatty Liver Disease: Time for Action”
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
